Analysts Set HilleVax, Inc. (NASDAQ:HLVX) Target Price at $9.20

Shares of HilleVax, Inc. (NASDAQ:HLVX) have been given a consensus rating of “Hold” by the six research firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.20.

Several research analysts have weighed in on HLVX shares. Guggenheim downgraded HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Stifel Nicolaus downgraded HilleVax from a “buy” rating to a “hold” rating and lowered their target price for the company from $34.00 to $3.00 in a research note on Tuesday. SVB Leerink downgraded HilleVax from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $28.00 to $2.00 in a research note on Tuesday. JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 price target (down from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Finally, HC Wainwright restated a “neutral” rating and issued a $2.00 price target (down from $28.00) on shares of HilleVax in a research note on Tuesday.

Insider Activity at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total transaction of $88,380.00. Following the sale, the director now directly owns 764,878 shares in the company, valued at $11,266,652.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 12,898 shares of company stock worth $193,766 over the last three months. 71.10% of the stock is currently owned by corporate insiders.

Institutional Trading of HilleVax

A number of institutional investors have recently bought and sold shares of the company. EntryPoint Capital LLC acquired a new position in shares of HilleVax in the first quarter worth $80,000. Swiss National Bank lifted its position in shares of HilleVax by 22.4% in the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after acquiring an additional 7,000 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of HilleVax in the fourth quarter valued at $139,000. Tidal Investments LLC purchased a new stake in shares of HilleVax in the first quarter valued at $207,000. Finally, abrdn plc purchased a new stake in shares of HilleVax in the fourth quarter valued at $433,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Trading Up 4.8 %

Shares of HLVX stock opened at $1.75 on Wednesday. The business’s 50 day moving average is $12.56 and its two-hundred day moving average is $14.41. HilleVax has a twelve month low of $1.55 and a twelve month high of $20.22. The company has a market capitalization of $87.01 million, a P/E ratio of -0.53 and a beta of 0.78. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11.

HilleVax (NASDAQ:HLVX) last announced its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.13). Equities analysts forecast that HilleVax will post -2.54 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.